查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1867124

黏液囊炎治療市場按治療方法、產品類型、應用部位和最終用戶分類－2025-2032年全球預測

Bursitis Treatment Market by Treatment Type, Product Category, Application Site, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，黏液囊炎治療市場將成長至 118.2 億美元，複合年成長率為 4.77%。

主要市場統計數據
基準年 2024 81.4億美元
預計年份：2025年 85.4億美元
預測年份：2032年 118.2億美元
複合年成長率 (%) 4.77%

簡要介紹黏液囊炎的治療途徑、患者負擔、跨專業協作以及影響當代臨床實踐的系統性因素。

黏液囊炎是一種常見但常被漏診的疾病，它會導致不同患者族群疼痛和功能障礙。臨床表現多樣，從急性發炎發作到慢性、活動受限的疾病，後者會影響工作和休閒活動。治療策略包括保守的自我護理、藥物治療、影像導引注射、復健干預，以及在特定情況下進行手術。人口結構的變化，包括人口老化、耐力運動和高強度運動參與度的提高，以及持續高發生率的代謝性疾病和風濕性疾病合併症，都增加了疾病診療的複雜性。

變革性的臨床、技術和供應趨勢正在獎勵黏液囊炎管理中的治療決策、護理服務模式和相關人員的激勵機制。

過去幾年，由於臨床創新、醫療服務模式的演變以及相關人員期望的改變，黏液囊炎的治療模式發生了顯著變化。再生醫學和生物目標療法的進步為傳統的皮質類固醇療法提供了替代方案，而成像技術和超音波引導技術的進步則提高了注射治療的精準性和安全性。同時，微創手術技術，特別是關節鏡手術，最佳化了手術適應症，並縮短了合適患者的復原時間。

美國近期關稅措施對黏液囊炎治療管道的採購、價格壓力、供應彈性和治療方法可近性的影響

美國近期關稅調整正對整個醫療保健供應鏈和藥品價值鏈產生連鎖反應，其累積效應影響治療方案的可近性、採購方式和成本結構。進口醫療設備、注射劑和生技藥品原料的關稅上漲推高了部分產品的到岸成本，促使供應鏈相關人員重新評估籌資策略。因此，一些製造商和經銷商正在加速供應商網路的多元化，考慮將關鍵零件的生產轉移到近岸或回流，並協商其他商業條款以維持利潤率並確保向醫療保健機構穩定供應。

清楚了解治療方法、產品類別、解剖應用部位和臨床環境對於解釋應用模式和臨床工作流程至關重要。

從細分觀點，我們可以發現治療方法應用、最活躍的相關人員以及創新領域整合的重要細微差別。從治療方法方式來看，照護範圍涵蓋了從冰敷、休息和煞車、熱敷等家庭措施，到包括非處方和處方非類固醇消炎劑在內的藥物治療，再到以皮質類固醇注射為主的注射療法，以及透明質酸和富血小板血漿療法等新興療法。物理治療包括冷療、運動療法和手法治療。同時，外科手術通常分為關節鏡和開放性手術。每個細分領域都呈現出獨特的模式。保守的居家照護和口服藥物通常作為初始步驟，優先考慮可及性和低成本；而當症狀持續或功能目標需要更積極的治療時，通常會選擇注射療法和外科手術。

關鍵區域差異，包括實踐模式、報銷方式、監管管道和供應鏈因素，影響全球主要市場的臨床應用

區域趨勢對黏液囊炎的診斷、治療和報銷方式有顯著影響，各大區域呈現不同的模式。在美洲，人們往往更重視快速獲得介入治療和完善的門診管道，而私人醫療覆蓋範圍和日間手術中心的擴張則影響注射療法和關節鏡療法的分佈。在歐洲、中東和非洲，報銷系統、管理體制以及先進生技藥品取得途徑的區域差異導致了實踐差異較大。在許多市場，集中採購和統一的國家指南促使人們採用高成本的治療方法，而公共醫療體系在製定治療標準方面發揮著舉足輕重的作用。在亞太地區，人口結構趨勢，例如一些國家人口快速老化以及另一些國家較高的體育參與率，正在推動對保守治療和介入治療的需求。同時，製造地和區域供應鏈也影響藥品的供應和定價趨勢。

在黏液囊炎治療及相關服務的商業性格局中，競爭角色、策略聯盟和以證據為基礎的差異化策略進行了深入分析。

黏液囊炎治療生態系統的競爭動態呈現出多元化的參與企業組成，其中包括成熟的製藥企業、醫療設備公司、生物製劑和再生醫學研發企業、數位醫療供應商以及支持分銷和臨床培訓的服務供應商。現有企業憑藉其規模、臨床關係和豐富的產品系列，維持與醫院和門診中心的合作關係。同時，小規模的專業公司則專注於利基創新，特別是再生醫學注射、照護現場生技藥品處理和新型給藥系統。此外，數位治療方法和遠距復健服務提供者也日益受到重視，它們能夠幫助患者長期堅持運動方案，並促進遠距臨床醫生的指導。

為製造商、醫療服務提供者和支付方提供切實可行的、以證據為基礎的策略建議，以提高臨床價值、增強供應韌性並改善以患者為中心的治療效果。

產業領導者和臨床計畫負責人應採取多管齊下的策略，以充分發揮臨床價值、改善患者療效並降低商業性風險。首先，優先考慮新型注射療法和再生醫學方案的高品質證據至關重要。將隨機對照試驗與務實的真實世界研究結合，將有助於加強與支付方的合作，並促進指南的採納。其次，供應鏈多元化以及探索關鍵零件的近岸外包方案，可以降低關稅波動和運輸中斷帶來的風險。同時，與集團採購組織達成策略協議，有助於穩定價格和供應。第三，投資臨床醫生教育以及超音波引導注射和微創手術的結構化實施項目，將有助於促進這些技術的合理應用，並降低療效的差異性。

本研究採用嚴謹的混合方法調查方法，結合專家訪談、臨床文獻綜合、供應鏈分析和利用資料三角驗證，以確保研究結果的可靠性。

支持這些發現的研究採用了多層次的調查方法，對臨床實踐模式、採購行為和創新趨勢進行三角驗證。主要資料來源包括對骨科醫生、物理治療師、介入性疼痛專家、門診手術經理和支付方醫療總監進行結構化訪談，以收集他們對治療選擇、實施障礙和營運限制的現場觀點。次要分析則利用同行評審的臨床文獻、專業學會指南和監管文件，評估藥物、注射和康復手術方法的相對證據基礎。供應鏈圖譜和貿易數據分析揭示了採購方面的脆弱性以及關稅波動對零件供應的潛在影響。

摘要重點闡述了臨床創新、醫療服務模式轉型、支付方壓力和醫療資源韌性這四者如何共同塑造黏液囊炎治療的未來。

總而言之，黏液囊炎的治療管理正受到多種因素的共同影響：生技藥品和影像引導介入治療的創新、遠距和居家照護的普及、支付方對療效和成本效益日益重視，以及供應鏈壓力對產品供應和定價的影響。這些動態既給臨床和商業領域的相關人員帶來了挑戰，也帶來了機會。臨床醫師需要在整合新治療方法的同時，維持實證治療管道；製造商必須展現出明顯的比較優勢；醫療系統必須制定穩健的籌資策略，以支持患者持續獲得全面的醫療服務。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴大超音波引導下皮質類固醇注射的應用範圍，以提高黏液囊炎治療的準確性
  • 擴大微創針刺術的應用範圍，以加快滑囊癒合並縮短恢復時間
  • 開發一種新型長效透明質酸配方，用於緩解肩部和髖部黏液囊炎疼痛
  • 將穿戴式運動感測器整合到黏液囊炎復健通訊協定中，用於即時監測關節負荷
  • 運動醫學專業人士對富血小板血漿療法治療難治性滑囊炎的興趣日益濃厚
  • 擴大家用冷卻和加壓系統（具備智慧溫控功能）在黏液囊炎發炎管理的應用

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

第8章 依治療方法的黏液囊炎治療市場

  • 居家照護
    • 冷療
    • 臥床休息
    • 熱敷
  • 注射療法
    • 皮質類固醇注射
    • 玻尿酸注射
    • 富血小板血漿療法
  • 口服藥物
    • 非處方非類固醇消炎劑
    • 處方箋非類固醇消炎劑
  • 物理治療
    • 冷凍療法
    • 運動療法
    • 手法治療
  • 手術介入
    • 關節鏡手術
    • 開放性手術

第9章 依產品類型的黏液囊炎治療市場

  • 抗生素
  • 生技藥品
  • 皮質類固醇
  • 非類固醇消炎劑

第10章黏液囊炎

  • 彎頭
  • 腳跟
  • 髖關節
  • 膝蓋
  • 肩膀

第11章 以最終用戶分類的黏液囊炎治療市場

  • 門診手術中心
  • 居家醫療環境
  • 醫院
  • 整形外科診所
  • 運動醫學中心

第12章 各地區黏液囊炎治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章黏液囊炎治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國黏液囊炎治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Pfizer Inc.
    • Bayer AG
    • Johnson & Johnson
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • GlaxoSmithKline plc
    • Sanofi SA
    • Merck & Co., Inc.
    • Zimmer Biomet Holdings, Inc.
    • Stryker Corporation
Product Code: MRR-5D693B46C73C

The Bursitis Treatment Market is projected to grow by USD 11.82 billion at a CAGR of 4.77% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 8.14 billion
Estimated Year [2025] USD 8.54 billion
Forecast Year [2032] USD 11.82 billion
CAGR (%) 4.77%

A concise introduction to bursitis treatment pathways, patient burden, multidisciplinary care, and the systemic forces shaping contemporary clinical practice

Bursitis represents a common yet often underestimated source of pain and functional limitation across diverse patient populations. In clinical practice, presentations range from acute inflammatory flares to chronic, activity-limiting conditions that impair work performance and recreational participation. Management strategies span conservative self-care measures, pharmacologic treatment, image-guided injections, rehabilitative interventions, and, in select cases, surgical procedures. Demographic shifts such as population aging, rising participation in endurance and high-impact sports, and persistent rates of comorbid metabolic and rheumatologic conditions have collectively increased the complexity of care pathways for this condition.

In addition, evolving expectations around rapid recovery, minimally invasive approaches, and minimized opioid exposure shape both clinician decision-making and payer scrutiny. Care delivery has also been altered by expanded remote care modalities; patients increasingly seek timely advice and guided rehabilitation that reduce the need for in-person visits. Moreover, the growing emphasis on outcomes, functional restoration, and cost-effective care has prompted multidisciplinary collaboration among primary care physicians, orthopedic specialists, physiotherapists, and pain management teams. This introduction sets the stage for a deeper examination of market dynamics, treatment innovations, reimbursement influences, and operational pressures that together define the contemporary landscape of bursitis treatment.

Transformative clinical, technological, and supply dynamics that are redefining treatment decisions, care delivery models, and stakeholder incentives in bursitis management

Over the last several years, the treatment landscape for bursitis has undergone substantive transformation driven by clinical innovation, care delivery evolution, and shifting stakeholder expectations. Advances in regenerative medicine and targeted biologic therapies have introduced alternatives to traditional corticosteroid approaches, while improved imaging techniques and ultrasound guidance have increased the precision and safety of injectable interventions. Concurrently, minimally invasive surgical techniques, particularly arthroscopic methods, have refined indications for operative management and reduced convalescence times for appropriate candidates.

Complementing therapeutic innovation, digital health enablers such as tele-rehabilitation platforms, remote monitoring, and patient-facing education tools have extended the reach of physical therapy and self-management programs. These tools are increasingly integrated into care pathways to support adherence to exercise therapy, facilitate clinician oversight, and provide real-time feedback on recovery trajectories. On the payer and provider sides, value-based contracting and outcome-focused procurement pressures are incentivizing evidence generation and cost-effectiveness studies, which in turn shape adoption patterns. Finally, supply chain volatility and an increased emphasis on domestic resilience are causing manufacturers and health systems to reassess sourcing strategies for implants, injectables, and home-care devices. Taken together, these shifts are moving the field toward more personalized, data-driven, and care-continuum-oriented approaches that prioritize measurable functional outcomes and patient experience.

How recent United States tariff measures are reshaping procurement, pricing pressures, supply resilience, and therapeutic availability across bursitis care pathways

Recent tariff changes in the United States have reverberated through the medical supply and pharmaceutical value chains, producing cumulative effects that influence treatment availability, procurement practices, and cost structures. Tariffs that affect imported medical devices, injectables, and biologic inputs increase the landed cost of certain products, prompting supply chain actors to reassess sourcing strategies. Consequently, some manufacturers and distributors have accelerated diversification of supplier networks, considered nearshoring or reshoring critical components, and negotiated alternative commercial terms to preserve margins and maintain consistent availability to providers.

Clinically, these procurement responses can influence the mix of therapies offered: higher device or biologic costs may lead health systems and outpatient centers to re-evaluate formularies and standard operating procedures, favoring therapeutics with stronger cost-effectiveness evidence or lower logistic complexity. For home-care modalities and over-the-counter products, tariff-driven price pressures can affect retail pricing and patient out-of-pocket burdens, which in turn shape adherence to noninvasive regimens. Additionally, tariff-induced cost volatility encourages buyers to leverage longer-term contracting, group purchasing organizations, and strategic inventory buffering to mitigate disruption.

At a strategic level, renewed policy-driven cost pressures stimulate investment in domestic manufacturing capacity, increase interest in alternative materials and technologies that bypass tariffed inputs, and intensify collaboration between clinicians, supply chain managers, and procurement teams. While tariffs do not directly change clinical efficacy, their secondary effects on availability, pricing, and procurement behavior can alter the landscape in which therapeutic choices are made, emphasizing resilience, evidence-backed value, and strategic contracting as key mitigation levers.

Clear segmentation-driven insights into therapeutic modalities, product classes, anatomical applications, and care settings that explain adoption patterns and clinical workflows

A granular segmentation lens reveals important nuances in how treatments are applied, which stakeholders are most active, and where innovation is concentrated. When treatments are viewed through the prism of therapy modality, care ranges from home-based measures-such as ice therapy, rest and immobilization, and warm compress applications-through pharmacologic approaches that include both over-the-counter and prescription nonsteroidal anti-inflammatory drugs, to injectable therapies where corticosteroid injections remain a mainstay and emerging options include hyaluronic acid and platelet-rich plasma therapy. Physical therapy practices encompass cryotherapy, exercise therapy, and manual therapy, while surgical interventions are generally divided between arthroscopic and open surgical approaches. Each of these subsegments demonstrates distinct patterns: conservative home care and oral medication often serve as initial steps that prioritize accessibility and low cost, whereas injectable therapy and surgical intervention are typically pursued when symptoms persist or functional goals demand more aggressive management.

From a product-category perspective, antibiotics, biologics, corticosteroids, and nonsteroidal anti-inflammatory drugs play discrete roles with differing regulatory profiles, evidence requirements, and distribution pathways. Biologics and advanced regenerative products, for example, require distinct cold-chain logistics and clinical training for administration compared with small-molecule NSAIDs. Considering anatomical application sites, treatment selection is influenced by structural variation across the elbow, heel, hip, knee, and shoulder; site-specific biomechanical demands and patient activity levels drive clinical decision-making and rehabilitation planning. Finally, the end-user landscape spans ambulatory surgical centers, home care settings, hospitals, orthopedic clinics, and sports medicine centers, each with unique purchasing processes, clinical workflows, and volume profiles. Understanding how these segmentation axes interact is essential for tailoring clinical protocols, commercial strategies, and evidence-generation programs to real-world use cases.

Key regional distinctions in practice patterns, reimbursement realities, regulatory pathways, and supply chain factors that influence clinical adoption across major global markets

Regional dynamics materially influence how bursitis is diagnosed, treated, and reimbursed, with distinct patterns emerging across major geographies. In the Americas, care delivery often emphasizes rapid access to interventional procedures and well-established outpatient pathways; private payer mix and ambulatory surgical center growth shape the distribution of injectable therapies and arthroscopic procedures. Moving to Europe, Middle East & Africa, practice variation is greater due to heterogeneous reimbursement systems, regulatory regimes, and access to advanced biologics; in many markets, centralized procurement and national guideline alignment influence the uptake of higher-cost therapeutics, and public systems play an outsized role in defining standard of care. Across the Asia-Pacific region, demographic trends-such as rapidly aging populations in some countries and high sports participation in others-drive demand for both conservative and interventional approaches, while manufacturing hubs and regional supply chains influence availability and pricing dynamics.

Across all regions, the pace of digital adoption, tele-rehabilitation, and training for ultrasound-guided injections varies, affecting the extent to which remote care or image-guided interventions are integrated into routine practice. Moreover, regional regulatory pathways for novel biologics and cell-based therapies determine the speed with which evidence is translated into clinical availability. Trade policies and logistics infrastructure further modulate the reliability of product supply, and regional differences in clinical guideline development and specialist density shape where care is concentrated, whether that be in hospital systems, specialty clinics, or community-based settings.

Insightful analysis of competitive roles, strategic partnerships, and evidence-driven differentiation shaping the commercial landscape for bursitis therapeutics and services

Competitive dynamics within the bursitis treatment ecosystem reflect a heterogeneous mix of established pharmaceutical manufacturers, medical device companies, specialty biologics and regenerative medicine developers, digital health vendors, and service providers that support distribution and clinical training. Incumbent players continue to leverage scale, clinical relationships, and broad product portfolios to maintain access across hospitals and ambulatory centers, while smaller specialty firms focus on niche innovations-particularly in regenerative injections, point-of-care biologic processing, and novel delivery systems. At the same time, digital therapeutics and tele-rehabilitation suppliers are increasing their relevance by enabling long-term adherence to exercise therapy and facilitating remote clinician oversight.

Strategic behavior includes targeted partnerships between device or biologic developers and clinical networks to generate real-world evidence and to accelerate guideline adoption. Contract manufacturing organizations and logistics specialists also play a pivotal role, particularly for temperature-sensitive biologics and single-use procedural kits. Across the competitive landscape, differentiation increasingly depends on the strength and transparency of clinical evidence, the quality of training and clinician support programs, and the ability to demonstrate consistent outcomes in routine practice. Companies that can integrate evidence generation with pragmatic implementation support, while also addressing payer concerns regarding cost-effectiveness, are positioned to gain preferential access to procurement decision-makers and long-term contracts.

Practical and evidence-focused strategic recommendations for manufacturers, providers, and payers to enhance clinical value, supply resilience, and patient-centered outcomes

Industry leaders and clinical program directors should adopt a multi-pronged strategy to capture clinical value, improve patient outcomes, and mitigate commercial risk. First, prioritizing high-quality evidence generation for novel injectables and regenerative options is essential; randomized controlled trials complemented by pragmatic real-world studies will support payer engagement and guideline inclusion. Second, diversifying supply chains and exploring nearshoring options for critical components can reduce exposure to tariff volatility and shipping disruptions, while strategic contracting with group purchasers can stabilize pricing and availability. Third, investing in clinician education and structured implementation programs for ultrasound-guided injections and minimally invasive procedures will facilitate appropriate adoption and reduce variability in outcomes.

Additionally, integrating tele-rehabilitation and patient-facing adherence tools into care pathways can improve functional recovery rates and reduce downstream utilization of invasive procedures. Value-based contracting models that link reimbursement to patient-reported outcomes and functional benchmarks should be explored with payers to align incentives around meaningful recovery. Finally, companies and providers should develop clear, patient-centered communication frameworks to set expectations for recovery timelines, nonpharmacologic management, and the trade-offs between short-term symptom relief and longer-term tissue healing, thereby enhancing shared decision-making and adherence to conservative regimens when appropriate.

A rigorous mixed-methods research methodology combining expert interviews, clinical literature synthesis, supply chain analysis, and utilization data triangulation to ensure robust findings

The research underpinning these insights combined a layered methodology designed to triangulate clinical practice patterns, procurement behaviors, and innovation trends. Primary inputs included structured interviews with orthopedists, physiotherapists, interventional pain specialists, ambulatory surgery managers, and payer medical directors to capture frontline perspectives on treatment selection, barriers to adoption, and operational constraints. Secondary analysis drew upon peer-reviewed clinical literature, professional society guidelines, and regulatory filings to assess the comparative evidence base for pharmacologic, injectable, rehabilitative, and surgical approaches. Supply chain mapping and trade data reviews were used to understand sourcing vulnerabilities and the potential impacts of tariff shifts on component availability.

Wherever possible, qualitative findings were cross-checked with anonymized claims and utilization datasets to validate patterns of service delivery and care transitions. The methodology prioritized transparency about limitations: for example, national-level heterogeneity in coding practices can complicate cross-country comparisons, and emerging biologic technologies may lack long-term outcome data. Ethical safeguards included informed consent for interviews and de-identification of proprietary procurement information. Taken together, this mixed-methods approach offers a robust foundation for the insights presented while acknowledging areas where further prospective data collection would strengthen causal inference.

Concluding synthesis highlighting the intersection of clinical innovation, care delivery transformation, payer pressures, and supply resilience shaping future bursitis care

In summary, the management of bursitis is being reshaped by converging forces: therapeutic innovation in biologics and image-guided interventions; expanding capability for remote and home-based care; heightened payer emphasis on outcomes and cost-effectiveness; and supply chain pressures that influence product availability and pricing. These dynamics create both challenges and opportunities for stakeholders across the clinical and commercial spectrum. Clinicians are tasked with integrating new modalities while maintaining evidence-based pathways, manufacturers must demonstrate clear comparative value, and health systems need to design resilient procurement strategies that support consistent access to a full continuum of care.

Moving forward, the most successful programs will be those that align rigorous clinical evidence with pragmatic implementation supports, leverage digital tools to enhance recovery and adherence, and proactively manage supply risk through diversified sourcing and strategic contracting. By focusing on measurable functional outcomes and patient-centered care, stakeholders can improve recovery trajectories while ensuring sustainable delivery models that are responsive to evolving regulatory and commercial conditions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising use of ultrasound-guided corticosteroid injections to improve bursitis treatment precision
  • 5.2. Expansion of minimally invasive needle fenestration techniques to accelerate bursa healing and reduce recovery time
  • 5.3. Development of novel hyaluronic acid formulations targeting shoulder and hip bursitis pain relief with longer duration
  • 5.4. Integration of wearable motion sensors for real-time monitoring of joint stress in bursitis rehabilitation protocols
  • 5.5. Increasing interest in platelet-rich plasma therapies for refractory bursitis cases among sports medicine practitioners
  • 5.6. Growth of home-use cold compression systems enhanced by smart temperature control to manage bursitis inflammation

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bursitis Treatment Market, by Treatment Type

  • 8.1. Home Care
    • 8.1.1. Ice Therapy
    • 8.1.2. Rest Immobilization
    • 8.1.3. Warm Compress
  • 8.2. Injectable Therapy
    • 8.2.1. Corticosteroid Injections
    • 8.2.2. Hyaluronic Acid Injections
    • 8.2.3. Platelet-Rich Plasma Therapy
  • 8.3. Oral Medication
    • 8.3.1. Over-The-Counter Nonsteroidal Anti-Inflammatory Drugs
    • 8.3.2. Prescription Nonsteroidal Anti-Inflammatory Drugs
  • 8.4. Physical Therapy
    • 8.4.1. Cryotherapy
    • 8.4.2. Exercise Therapy
    • 8.4.3. Manual Therapy
  • 8.5. Surgical Intervention
    • 8.5.1. Arthroscopic Surgery
    • 8.5.2. Open Surgery

9. Bursitis Treatment Market, by Product Category

  • 9.1. Antibiotics
  • 9.2. Biologics
  • 9.3. Corticosteroids
  • 9.4. Nonsteroidal Anti-Inflammatory Drugs

10. Bursitis Treatment Market, by Application Site

  • 10.1. Elbow
  • 10.2. Heel
  • 10.3. Hip
  • 10.4. Knee
  • 10.5. Shoulder

11. Bursitis Treatment Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Home Care Settings
  • 11.3. Hospitals
  • 11.4. Orthopedic Clinics
  • 11.5. Sports Medicine Centers

12. Bursitis Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Bursitis Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Bursitis Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Pfizer Inc.
    • 15.3.2. Bayer AG
    • 15.3.3. Johnson & Johnson
    • 15.3.4. Novartis AG
    • 15.3.5. Teva Pharmaceutical Industries Ltd.
    • 15.3.6. GlaxoSmithKline plc
    • 15.3.7. Sanofi S.A.
    • 15.3.8. Merck & Co., Inc.
    • 15.3.9. Zimmer Biomet Holdings, Inc.
    • 15.3.10. Stryker Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL BURSITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BURSITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. BURSITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BURSITIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BURSITIS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BURSITIS TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ICE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ICE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ICE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ICE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ICE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ICE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REST IMMOBILIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REST IMMOBILIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REST IMMOBILIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REST IMMOBILIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REST IMMOBILIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REST IMMOBILIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY WARM COMPRESS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY WARM COMPRESS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY WARM COMPRESS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY WARM COMPRESS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY WARM COMPRESS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY WARM COMPRESS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PLATELET-RICH PLASMA THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PLATELET-RICH PLASMA THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PLATELET-RICH PLASMA THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PLATELET-RICH PLASMA THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PLATELET-RICH PLASMA THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PLATELET-RICH PLASMA THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OVER-THE-COUNTER NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OVER-THE-COUNTER NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OVER-THE-COUNTER NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OVER-THE-COUNTER NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OVER-THE-COUNTER NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OVER-THE-COUNTER NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRESCRIPTION NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRESCRIPTION NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRESCRIPTION NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRESCRIPTION NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRESCRIPTION NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRESCRIPTION NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CRYOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CRYOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CRYOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CRYOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CRYOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CRYOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY MANUAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY MANUAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY MANUAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY MANUAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY MANUAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY MANUAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ARTHROSCOPIC SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ARTHROSCOPIC SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ARTHROSCOPIC SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ARTHROSCOPIC SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ARTHROSCOPIC SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ARTHROSCOPIC SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OPEN SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OPEN SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OPEN SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OPEN SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OPEN SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OPEN SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ELBOW, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ELBOW, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ELBOW, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ELBOW, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ELBOW, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ELBOW, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HEEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HEEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HEEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HEEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HEEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HEEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HIP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HIP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HIP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HIP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HIP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HIP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY KNEE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY KNEE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY KNEE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY KNEE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY KNEE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY KNEE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SHOULDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SHOULDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SHOULDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SHOULDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SHOULDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SHOULDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORTHOPEDIC CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORTHOPEDIC CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORTHOPEDIC CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORTHOPEDIC CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORTHOPEDIC CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORTHOPEDIC CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SPORTS MEDICINE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SPORTS MEDICINE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SPORTS MEDICINE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SPORTS MEDICINE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SPORTS MEDICINE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SPORTS MEDICINE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE BURSITIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)

TABLE